In eighteen months, the private equity (PE) and growth equity arms of Goldman Sachs Asset Management (GSAM) have made three large healthcare bets that are focused on a similar patient personality archetype.
They co-own MDVIP, the largest concierge medicine network in the United States [1]
They led the $150 million Series E for Aidoc, a foundation-model clinical artificial intelligence (AI) company whose software now reads scans across roughly 2,000 hospitals [3].
They led the $55 million Series C for Navina, an AI copilot built to surface patient insights at the point of care, which is precisely the workflow a small concierge practice runs every day [4].
It is clear that Goldman is making a bet on a new style of medicine and while these bets are not large in comparison to Goldman's AUM, they are large for the AI and concierge medicine ecosystem.
The Anchor: MDVIP
Start with the asset everything else orbits.
In October 2021, GSAM and Charlesbank Capital Partners closed on majority ownership of MDVIP through a 50/50 control structure with shared governance [1][5]. The seller was Leonard Green & Partners, with Summit Partners rolling a minority stake [1]. Charlesbank, a Boston-based middle-market PE firm with about $24 billion in assets under management (AUM) as of September 2025, is the operational lead on healthcare deals [6]. GSAM provides the capital scale, regulatory familiarity, and a parallel healthcare-AI deal book.
MDVIP today serves roughly 362,000 patients through about 1,100 affiliated physicians across 44 states [2]. Annual membership fees, which fund longer visits, smaller panels, and same-day access, sit at roughly $1,500 to $2,000 per patient. That is the entry tier of concierge medicine, well below the broader concierge market range of $3,000 to over $40,000 per year. Patients enrolled in MDVIP keep their commercial insurance for everything outside primary care.
The hold is now in its fifth year. PE funds of this vintage typically run a banker process between years five and seven. A 2026 second half or 2027 exit would reset comparable valuations for every other concierge platform that follows, including Revelstoke's Griffin Concierge Medical, Blue Sea Capital's SignatureMD, Shore Capital's Specialdocs, and the founder-owned platforms contemplating a first PE round.
For context on how PE is reshaping the entire category, see our analysis of the growth of private equity in concierge medicine.
The Diagnostic AI Bet: Aidoc
On April 30, 2026, Aidoc closed a $150 million Series E led by GSAM Growth Equity, with participation from General Catalyst, SoftBank Vision Fund 2, and Nvidia's venture capital (VC) arm NVentures [3]. It was Aidoc's second $150 million round in under a year, taking total funding past $500 million [3].
Aidoc builds foundation-model clinical AI for radiology, cardiology, and neurovascular and vascular imaging. Its product, called CARE for Clinical AI Reasoning Engine, received Food and Drug Administration (FDA) clearance earlier in 2026 and analyzes roughly 60 million patient cases per year across the hospitals it serves [3].
On the surface, Aidoc is an enterprise hospital tool, not a patient-facing one. But concierge physicians order the imaging studies that Aidoc reads. When a concierge cardiologist sends a member for a coronary computed tomography angiogram (CCTA), the read that comes back has increasingly been touched by foundation-model AI. As hospital adoption grows, the speed and consistency of those reads will define how quickly a concierge physician can act on findings. Owning the imaging-AI substrate has indirect leverage over concierge primary care.
The Aidoc round also lands inside a broader pattern: AI-imaging companies are commanding the kind of valuations the early scribe leaders did in 2025. We covered the parallel category-pricing event last week in our piece on what Abridge's $300M Series E means for concierge medicine.
The Practice Workflow Bet: Navina
In April 2026, GSAM led a $55 million Series C for Navina [4]. Navina builds an AI copilot that ingests a patient's full chart, payer data, and outside records, then surfaces what a clinician needs to know in under a minute. It is built for small clinical teams.
This deal is interesting for concierge doctors. As concierge medicine is structurally a small-team product. A typical concierge primary care physician sees fewer than 300 patients, compared with 2,000 to 2,500 in a traditional fee-for-service practice. Smaller panels mean each patient encounter carries more weight per minute and more dependence on the physician knowing the patient's full medical context cold.
Navina's product proposition, faster context retrieval for time-rich physicians, fits the concierge workflow more cleanly than it fits any hospital outpatient clinic. The fact that GSAM led the round, while also co-owning MDVIP, is the signal. The same investor that owns the largest concierge network is funding the workflow software that small concierge practices would use.
The Pattern
There is a precedent for how Charlesbank and GSAM work together. In 2019, the same two firms co-invested in MyEyeDr, an optical retail platform that has since grown to over 700 locations [6]. The co-governance structure used at MyEyeDr was the playbook repeated for MDVIP two years later. Two healthcare consolidation platforms, same two sponsors, same playbook.
Layer the AI deals on top of that. GSAM is now an investor in:
The largest concierge medicine network (MDVIP)
The AI tool that reads the scans concierge physicians order (Aidoc)
The AI copilot built for the small-team workflow concierge physicians run (Navina)
This is what a concentrated healthcare-AI thesis looks like when it converges on a single delivery model. It is not a coincidence. It is what a sponsor does when it intends to bolt those tools into the platform it already owns, in time for the next sale process.
What To Watch
Three signals matter most over the next twelve months.
First, an MDVIP banker mandate. Any leak of a banker process, management changes, or audit-firm hires inside MDVIP would suggest the exit is on. A 2026-2027 exit is the single largest catalyst on the concierge calendar.
Second, an Aidoc or Navina pilot inside MDVIP. If MDVIP announces a pilot of either tool with its affiliated physicians, that closes the loop on the thesis. It would be the first time a major concierge network openly integrates a sponsor-portfolio AI product. Watch the MDVIP press room and the GSAM healthcare communications.
Third, a third joint Charlesbank and GSAM healthcare deal. Two co-investments (MyEyeDr 2019, MDVIP 2021) form a relationship. A third would form a strategy. The most likely shape: a multi-site primary care or specialty platform that gives the GSAM healthcare-AI tools a second deployment pad.
What This Means For Patients
If you already pay for MDVIP, your physician's workflow tools are likely to evolve faster than at independent concierge practices, simply because the parent company has portfolio-level access to the AI infrastructure being funded. That can be good. It also means your physician's documentation tools, scan reads, and patient summaries will increasingly carry GSAM's signature.
It is good to understand who is working together, how different doctors are accessing AI tech within private medicine and how the industry is evolving.
If you have not started looking, our patient guide on how to find a concierge doctor near you walks through the search step by step.
Sources
Charlesbank Capital Partners. (2021). Goldman Sachs Asset Management and Charlesbank Capital Partners Complete Acquisition of MDVIP Primary Care Network. Read on Charlesbank.com
Charlesbank Capital Partners. MDVIP investment page (network size, ownership structure, leadership). Read on Charlesbank.com
Fierce Healthcare. (2026). Aidoc banks $150M backed by Goldman Sachs to scale clinical AI foundation model. Read on FierceHealthcare.com
Fierce Healthcare. (2026). Navina reels in $55M Series C led by Goldman Sachs. Read on FierceHealthcare.com
PR Newswire. (2021). Goldman Sachs Asset Management and Charlesbank Capital Partners to Acquire Majority Ownership of MDVIP from Leonard Green & Partners and Summit Partners. Read on PRNewswire.com
Charlesbank Capital Partners. About Charlesbank (firm history, AUM, sectors, healthcare portfolio thesis). Read on Charlesbank.com